Roche In-licenses Amunix’s Half-life Extension Technology in US$1.5 B Deal
By Sharath Chandra Nakka
Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)
Published: 28 Jan-2020
DOI: 10.3833/pdr.v2020.i1.2505 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Building on its platform technology portfolio, Roche has entered into a technology licensing agreement with Amunix Pharmaceuticals for its half-life extension platform, XTEN®, to discover and develop novel therapeutics in non-oncology indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS